This phase III , double-masked , noninferiority study randomized patients with mild to moderate endogenous AU to receive difluprednate 0.05 % ( n = 56 ) four times daily , alternating with vehicle four times daily , or prednisolone acetate 1 % ( n = 54 ) eight times daily .